Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
There isn’t enough historical data to display yet.
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $6 · 2 analysts
Kezar Life Sciences stock holds steady as investors await next catalysts - AD HOC NEWS
Kezar Life Sciences stock holds steady as investors await next catalysts AD HOC NEWS
Kezar Life Sciences Inc. (KZR) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Kezar Life Sciences Inc. (KZR) Shareholding Pattern – Promoters, FIIs & DIIs valueresearchonline.com
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface - AD HOC NEWS
Kezar Life Sciences stock in focus after Aurinia tender offer and merger terms surface AD HOC NEWS
Kezar Life Sciences Inc (NASDAQ:KZR) - intelligentinvestor.com.au
Kezar Life Sciences Inc (NASDAQ:KZR) intelligentinvestor.com.au
Articles from Enodia Therapeutics and Kezar Life Sciences, Inc. - FinancialContent
Articles from Enodia Therapeutics and Kezar Life Sciences, Inc. FinancialContent
Kezar Life Sciences Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates Amid No Revenue - careplusvn.com
Kezar Life Sciences Q1 2026 Earnings: Clinical-Stage Biotech Misses EPS Estimates Amid No Revenue careplusvn.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 12. | After market close (AMC) | $-0.91 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 10. 18. | Jefferies | — | Downgrade | Buy → Hold | — | Jefferies: Buy → Hold |
| 2025. 10. 17. | William Blair | — | Downgrade | Outperform → Market Perform | — | William Blair: Outperform → Market Perform |
| 2025. 10. 17. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 07. 16. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
| 2024. 12. 19. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2024. 12. 02. | HC Wainwright & Co. | — | Maintain | Neutral → Neutral | — | HC Wainwright & Co.: Neutral |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 11,312 | $71.15K | 0.00% | — | New position |
